Overview

FTIH Study of ECC0509 in Healthy Volunteers

Status:
Recruiting

Trial end date:
2022-02-20

Target enrollment:

Participant gender:

Summary

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Eccanga Pty Ltd

Collaborator:

Syneos Health